> 7 VECTIBIX should not be administered in combination with IFL chemotherapy or with BEVACIZUMAB -containing chemotherapy. A high incidence of severe diarrhoea was observed when panitumumab was administered in combination with IFL (see section  4.4), and increased toxicity and deaths were seen when panitumumab was combined with BEVACIZUMAB and chemotherapy (see sections  4.4 and  5.1).
> The combination of VECTIBIX with OXALIPLATIN -containing chemotherapy is contraindicated for patients with mutant RAS m
